Brief: Arrowhead Pharmaceuticals Announces Nmpa Approval Of Redemplo® (Plozasiran)
07/01/2026 12:43
Jan 7 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS ANNOUNCES NMPA APPROVAL OF REDEMPLO® (PLOZASIRAN) FOR FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) IN CHINA ARROWHEAD PHARMACEUTICALS: NMPA APPROVAL TRIGGERS $10 MILLION MILESTONE PAYMENT TO BE PAID BY SANOFI TO ARROWHEAD SUBSIDIARY VISIRNA THERAPEUTICS Source text: ID:nBw8Hj8sya Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers